Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Blanca Ledezma

Faculty

Blanca Ledezma

MSN, NP, AOCNP

Department of Hematology Oncology Santa Monica, California

UCLA Health

Marissa Marti-Smith

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Ruth M O'Regan, MD

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Heather McArthur

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

    Program Schedule — Central Time

    5:30 PM – 6:00 PM — Registration and Dinner
    6:00 PM – 7:30 PM — Educational Meeting

    MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

    • Incidence, pathophysiology and clinical characteristics of HR-positive mBC
    • Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
    • Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
    • Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
    • Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

    MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

    • Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
    • Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
    • Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
    • FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
    • Identification of patients appropriate for treatment with elacestrant or imlunestrant

    MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

    • Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
    • Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
    • Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
    • Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

    MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

    • Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
    • Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
    • Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
    • Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
    • Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

    MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

    • Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
    • Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
    • Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
    • Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

    Target Audience
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

    Learning Objectives
    Upon completion of this activity, participants should be able to

    • Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
    • Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
    • Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
    • Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
    • Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
    • Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
    • Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

    Accreditation Statement
    Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    Credit Designation Statements
    This educational activity for 1.5 contact hours is provided by Research To Practice.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Credit Form
    To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

    Privacy Policy
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    Unlabeled/Unapproved Uses Notice
    There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

    Content Validation and Disclosures
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

    MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

    RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
    Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

    Supporters
    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

    Location
    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, TX 78205
    Hotel Phone: (210) 223-1000

    Meeting Room
    Grand Ballroom A-F (Third Floor)

    Directions
    The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

     

    Registration is now closed.

    Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Optimizing the Use of CDK4/6 Inhibitors in the Management of HR-Positive Breast Cancer

    A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

    Program Schedule — Central Time

    5:30 AM – 6:00 AM — Registration and Breakfast
    6:00 AM – 7:30 AM — Educational Meeting

    Location

    San Antonio Marriott Rivercenter
    101 Bowie St
    San Antonio, Texas
    Hotel Phone: (210) 223-1000

    Meeting Room

    Grand Ballroom A-F (Third Floor)

    No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

    Faculty

    Kelly Fischer

    Faculty

    Kelly Fischer

    MSN, FNP-BC

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Family Nurse Practitioner

    Marissa Marti-Smith

    Faculty

    Marissa Marti-Smith

    DNP, APRN, AGNP-C, AOCNP

    Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

    Nurse Practitioner

    Ruth M O'Regan, MD

    Faculty

    Ruth M O'Regan, MD

    University of Rochester Medical Center, Rochester, New York

    Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

    Strong Memorial Hospital, Rochester, New York

    Physician-in-Chief

    Wilmot Cancer Institute, Rochester, New York

    Associate Director of Education and Mentoring

    Rita Nanda

    Moderator

    Rita Nanda

    MD

    The University of Chicago, Chicago, Illinois

    Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

    Meeting space has been assigned to provide a symposium supported by Lilly and Novartis during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

      Program Schedule — Central Time
      5:30 AM – 6:00 AM — Registration and Breakfast
      6:00 AM – 7:30 AM — Educational Meeting

      MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

      • Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
      • Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
      • Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
      • Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

      MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

      • Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
      • Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
      • FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

      MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

      • Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
      • Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
      • Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
      • Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

      MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

      • Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
      • Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
      • Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

      MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

      • Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
      • Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
      • Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

      MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

      • Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
      • Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
      • Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
      • Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
      • Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

      MODULE 7: Practical Considerations with CDK4/6 Inhibitors

      • Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
      • Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
      • Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
      • Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

      Target Audience
      This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

      Learning Objectives
      Upon completion of this activity, participants should be able to

      • Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
      • Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
      • Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
      • Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
      • Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
      • Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

      Accreditation Statement
      Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

      Credit Designation Statements
      This educational activity for 1.5 contact hours is provided by Research To Practice.

      This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

      Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
      The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

      ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

      Credit Form
      To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

      Privacy Policy
      Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

      Unlabeled/Unapproved Uses Notice
      There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

      Content Validation and Disclosures
      Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

      FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

      Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

      MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

      RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
      Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

      Supporters
      This activity is supported by educational grants from Lilly and Novartis.

      Location
      San Antonio Marriott Rivercenter
      101 Bowie St
      San Antonio, TX 78205
      Hotel Phone: (210) 223-1000

      Meeting Room
      Grand Ballroom A-F (Third Floor)

      Directions
      The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

       

      Registration is now closed.